Method for producing gel-forming dextrane phosphates. RU patent 2455007.

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to chemical-pharmaceutical industry, medicine, biotechnology, and concerns a method for producing dextrane phosphate hydrogels which can find application in preparing prolonged preparations for treating oncological diseases, infectious diseases, immune disorders. The declared invention describes the method for producing polysaccharide phosphate hydrogels, involving processing of an initial polysaccharide in mixed orthophosphoric acid and phosphorus oxide (V) in an organic solvent medium in the presence of trialkylphosphate at temperature 30-70°C that is followed by washing of the prepared products, drying and processing in an aqueous solution of a mineral compound with the etherification process of dextrane conducted in a non-polar organic solvent medium of the low boiling point specified in hydrocarbons and their derivatives and processing of the prepared product in 0.005-0.5 M aqueous solutions of sodium carbonate, or sodium hydrocarbonate, or sodium hydroxide, or their mixtures to the value pH 3.0-8.0 to be set down in ethanol and dried at temperature 20-50°C.

EFFECT: invention allows producing dextrane phosphate characterised by high pharmacological activity indices.

9 ex, 4 tbl

IPC classes for russian patent Method for producing gel-forming dextrane phosphates. RU patent 2455007. (RU 2455007):

C08B37/02 - Dextran; Derivatives thereof

A61P35 - Antineoplastic agents

A61K31/721 - Medicinal preparations containing organic active ingredients

Another patents in same IPC classes:

Complex of folic acid or derivative thereof, pharmaceutical composition and uses of complex / 2280650
Invention relates to complex of general formula (X)n-Y, wherein X are identical or different and represent folic acid, folinic acid, dihydrofolic acid, tetrahydrofolic acid, tetrahyldopterine, pteroyl-polyglutamic acid, 2-deaminohydroxyfolic acid, 1-denitrofolic acid, 3-denitrofolic acid, 8-denitrofolic acid; Y represents polysaccharide different from arabinogalactane, selected from group containing glucanes, dextranes, polysaccharoses, fructosanes, heteropolysaccharides, homo- or heteropolysaccharide sulfates, ginseng pectin polysaccharide and other pectin polysaccharides, gumghatti, alginate, etc; or Y is selected from polyethylene oxide, methoxypolyethylene glycol and hydrophilic alcohol polymers; n >=1. Said complex permeates into in cell via pathway involving folic acid receptor on cell membrane. Complex of present invention is useful in production of pharmaceutical agents having antitumor activity.

Composition containing oridonin and applicable for treating resistant malignant tumours / 2455002
There are offered: using synergistically effective amounts of compounds of formula I (oridonin), II (particularly vogonin) and IV (particularly, 2,4,4'-trihydroxychalcone) for preparing a drug preparation for treating neoplasia resistant to a therapeutic agent, specified in a group consisting of prostate cancer, breast cancer, endometrial cancer, colon cancer, lung cancer, bladder cancer, testicular cancer, ovarian cancer, thyroid cancer and bone cancer; an appropriate composition and a method of treating. What is shown is: strong synergetic action of the ingredients of the composition according to the present invention. It makes them applicable in relatively low amounts to treating stage IV cancer or recurrent cancer which can be characterised by developed resistance to conventional chemotherapeutic agents.

Compound for stimulating signal pathways through il-15rbeta/gamma for purposes of inducing and/or stimulating activation and/or proliferation of il-15rbeta/gamma-positive cells such as nk- and/or t-cells, nucleic acid coding compound, expression vector, host cell, adjuvant for immunotherapeutic composition, pharmaceutical composition and therapeutic agent for treating condition or disease which requires higher activity of il-15, method for inducing and/or stimulating in vitro proliferation and/or activation of il-15rbeta/gamma-positive cells and method for making in vitro activated nk-and/or t-cells / 2454463
Compound contains IL-15 indirectly bound by covalent links with a polypeptide containing a sushi domain of an extra-cellular region of the alpha IL-15R subunit.

Metastin derivatives and use thereof / 2454425
Invention relates to stable metastin derivatives, having excellent biological activity. The disclosed metastin derivatives improve stability, gelation tendency is reduced, pharmacokinetics are also improved, and an excellent cancer metastasis suppressing activity or a cancer growth suppressing activity is exhibited.

13-ethyl-gona-1,3,5( 10), 8 (9)-tetraene-3,17β-diol diacetate, having anti-implantation and antioxidant activity / 2454424
Invention relates to a diacetate of racemic 18-ethyl-gona-1,3,5(10),8(9)-tetraene-3,17β-diol, having anti-implantation and antioxidant activity with low uterotropic action. Presence of antioxidant activity in said steroid is essential since compounds with such action can be agents for preventing oestrogen-dependent breast cancer.

Cytotoxic semi-synthetic macrolide antibiotic oligomycin a derivatives and synthesis method thereof / 2454420
Invention relates to novel antibiotic oligomycin A derivatives, having anti-tumour activity and low toxicity, of formula: , where R is a methanesulphonic acid (OSO3CH3) residue or an azide group (N3) and synthesis method and use thereof.

Pyridin-3-yl derivatives as immunomodulatory agents / 2454413
Invention refers to pyridine-3-yl derivatives of formula (I)

Quinoline derivatives / 2454411
Present invention refers to quinoline derivatives of formula I

Method of treating oncological disease by radiation therapy / 2454257
Invention refers to medicine, concerns treating cancer. The tumour is exposed to gamma photon with a radiation source cobalt-60 at gamma photon radiation energy 1.25 MeV. A patient takes herbal infusion 400-500 ml 30-40 min before the radiation therapy session: Alexandrian laurel leaves, burdock leaves, alder blossom, dill seeds, celandine herb, nettle herb and sage herb in equal portions. The plants are pre-dried in the shade to humidity 14-16 %, then each is taken in the amount of 100 g, mixed and powdered. The herbal powder 40-50 g is filled with boiling water 500-600 ml, boiled for 3 min, and settled for 2-3 hours. Between the radiation therapy sessions, the patient takes the infusion 200-250 ml twice a day, and after the termination of the therapeutic course, the infusion 200-250 ml is prescribed once a day.

Method of treating cervical cancer / 2454256
Invention refers to medicine, namely oncology, and can be used for treating cervical cancer. That is ensured by radiation teletherapy and brachytherapy. Each brachytherapy session is preceded by bringing the Hydrogel Coletex-M Tissue 3-5 ml to the tumour before 12-18 hours. Before gel contact, the Coletex-M Tissue is introduced. Further,1-1,5 hours prior to the brachytherapy session, the textile tissue is removed, and Hydrogel Coletex-ADL Tissue 4-6 ml is brought to the tumour. Preliminary, the Hydrogel Coletex-ADL Tissue is added with lidocaine to achieve the gel concentration 4-6%.

Method of photodynamic therapy of malignant growths / 2454255
Invention concerns medicine, oncology, and is applicable for photodynamic therapy of malignant growths. That is ensured by introducing a photosensitiser and conducting light illumination of the new growth at wave length corresponding to a maximum absorption of chlorine derivatives. The photosensitiser is presented by a gelatinous capsule with powder microparticles of chlorine derivatives mixed with lyophilised spirulina platensis. Each powder microparticle is coated with a protective acid-resistant film. The gelatinous capsule is introduced orally. Each gelatinous capsule contains the ingredients in the following proportions (Mg): chlorine derivatives - 1-1.5; spirulina platensis - 100-150; protective acid-resistant film - 50-75; calcium stearate - 0.5-0.75.

Method for disinvasion from avian coccidian oocysts / 2454995
Invention refers to veterinary science, namely protozoology, and is applicable in poultry farms for preventing avian coccidiosis. For this purpose, the environmental objects are processed with a disinfectant. The disinfectant is presented with an agent containing (wt %): alkyl triamine - 60, benzalkonium chloride - 5, glutamic acid tetrasodium salt - 4, auxiliary components - the rest. The disinfectant is used in a dose of 0.5 l per 1 sq. m with and exposed for 2 hours.

2-mercaptobenzoyl hydrazones of monose, having antimicrobial and antifungal activity / 2454423
Invention relates to use of 2-mercaptobenzoyl hydrazones of monose of formula (where the name of monose and value of radicals are listed in the table) as antimocrobial and antifungal agents.

Combination possessing antiaggregant, lipid-regulating and gastroprotective activities, pharmaceutical composition / 2453314
What is offered is a solid dosage pharmaceutical composition containing a combination of acetylsalicylic acid and ethylmethyl hydroxypyridine malate and ethylmethyl hydroxypyridine succinate possessing antiaggregant, lipid-regulating and gastroprotective activities. What is shown is substantial prolongation of shelf life of the solid dosage form.

Controlled release complex pharmaceutical composition containing angiotensin-ii receptor blockers and hydroximethylglutaryl-coa reductase inhibitors / 2453307
Declared invention refers to medicine. What is declared is a delayed release complex pharmaceutical composition containing a delayed release part and an immediate release part. The delayed release part contains AII-receptor blocker as an 'active ingredient'. The immediate release part contains HMG-CoA reductase inhibitor as an active ingredient.

Dermatological agent 'belemnit' for acne and psoriasis / 2453305
Invention refers to cosmetology and represents a dermatological agent for acne and psoriasis, containing Vaseline and mineral powder Belemnit, characterised by the fact that it additionally contains polyethylene glycol 200 and salicylic acid with the ingredients in the agent taken in certain proportions, wt %.

Method of selecting tactics of treating puerperas with post-natal purulent-septic diseases / 2453274
Invention relates to medicine, obstetrics, gynecology and includes estimation of puerperas' state, depending on which treatment tactics is selected. Severity of state is estimated by two groups of criteria of table No 3, presented in the description, by 1 point: absence of factors of risk of purulent-septic complications (PSC), subfebrile condition with single rise to 38°C, arrested by antibacterial therapy (ABT), absence of easily arrested intestine paresis after Cesarean section, the cervix of uterus is formed, presence of uterus involution in hysteroscopy at the background of treatment with endometrectomy or vacuum-aspiration, USE-data - increase and extension of uterus cavity by 0.5-1.0 cm, absence of deformation in the area of scar or deformation up to 0.5 cm, on uterus walls - linear echo-positive structures up to 0.2-0.3 cm thick, local sections of reduced myometrium echogenicity in the region of scars not larger than 1.5x1.5 cm, absence of infiltration, hematoma in the region of scars, improvement of laboratory indices in dynamics. Criteria of group 2 are estimated in 2 points: presence of PSC risk factors, long-lasting fever with resumption after finishing ABT, intestine paresis with absence of effect from intensive or repeated treatment courses, absence of tendency to formation of uterus cervix, stable uterus subinvolution, by USE data: extension of uterus cavity ≥1 cm, deformation in scar ≥0.5 cm, echopositive structures ≥0.4 cm, reduces echogenicity in scar zone ≥2.5×1.5 cm, hematoma or infiltrate in retrovesical space, in area of scars, absence of positive dynamics or change of laboratory indices to the worse. If state of puerpera is characterised by criteria of the first group to 7 points, it is estimated as uncomplicated form of disease, if - more than 7 points or at least by one criterion from group 2, as complicated form.

Method of treating myofascial pain accompanying spine osteochondrosis / 2452493
Invention refers to medicine, namely neurology, orthopaedics, reflexotherapy, physiotherapy exercises, recreation therapy and is applicable in integrated treatment of myofascial pain accompanying spine osteochondrosis. Pain management procedures are followed by a complex of exercises with using the HUBER apparatus consisting of seven staticodynamic exercises aimed at strengthening and activation of muscles of upper limb girdle, greater pectoral muscle, pelvic floor muscles and gluteal muscles. It is combined with loading and coordination improvement of left broadest muscle of back, left obliques, left lumbar quadrate muscle. Upper shoulder anchors, broadest muscle of back and rhomboid muscle are relaxed, and postural muscles are coordinated. Lumbar spine muscles are relaxed. Tone in upper extremity and back muscles is strengthened. It is followed by making exercises for activation of muscles of upper limb girdle, pectoral muscles, pelvic floor muscles, gluteal muscles. Then, the exercises for strengthening of lumbar muscles for the purpose of improving the body position coordination, relaxation of back ground of femoral and hip muscles, strengthening of abdominal wall muscles.

Anthelminthic agent / 2452489
Invention refers to veterinary parasitology, and may be recommended for treating cestodiasis and nematodosis.

Layered pharmaceutical compositions / 2452471
Layered pharmaceutical compositins for introduction of two or more pharmaceutically active ingredients involves two layers and an intermediate layer located between the first and second pharmaceutical layers. The first and second pharmaceutical layers contain pharmaceutically active ingredients specified in a group of Bupropion, Naltrexone and Zonisamide. The intermediate layer contains at least one monosaccharide sugar, disaccharide sugar or starch. The intermediate layer is formed for fast dissolution in vivo with the first and second pharmaceutical layers remaining intact, but physically separated. The layered composition is used for effective weight loss, loss of appetite and treatment of the obesity-related conditions.

Dental compositions for xerostomia / 2452465
Group of inventions refers to dental compositions for treating or preventing dry mouth syndrome. One of the versions of the composition for treating and/or preventing dry mouth syndrome and at least one accompanying pathology represents a composition containing at least one surfactant, at least one antimicrobial agent and at least one adhesive where at least one antimicrobial agent is sterically immobilised in a complex with one or more glycosaminoglycans. Said composition can represent a tooth paste, a tooth elixir or an oral spray. The other version of the composition contains at least one surfactant, at least one antimicrobial agent, and at least one adhesive; wherein at least one antimicrobial agent represents cetylpyridinium chloride in a complex with one or more glycosaminoglycans.